Enzon Pharmaceuticals, Inc.

ENZN

US2939041081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:40:24 2024-05-07 EDT			5-day change	1st Jan Change
0.0825 ^USD	+5.10%		-1.20%	-11.86%

03-20	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary

January 04, 2021 at 08:55 am

Enzon Pharmaceuticals, Inc. announced that Richard L. Feinstein, Enzon’s Chief Financial Officer, will assume the role of Secretary, as well as remain the Company’s Chief Financial Officer.

Latest news about Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-04	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-23	CI
Enzon Pharmaceuticals, Inc. Announces Executive Changes	21-01-04	CI
Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary	21-01-04	CI
Declaration of Voting Results Enzon Pharmaceuticals	20-12-21	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Enzon Pharmaceuticals Solicits Proxies from the Shareholders	20-11-03	CI
Enzon Pharmaceuticals to Seek Acquisition Opportunities	20-10-21	CI
Enzon Pharmaceuticals, Inc. Provides Information to the Shareholders	20-08-10	CI
Enzon Pharmaceuticals, Inc. Announces Board Changes	20-08-07	CI
Jonathan Couchman Nominates Candidates to the Board of Enzon Pharmaceuticals	20-08-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-07-29	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-30	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-19	CI

Chart Enzon Pharmaceuticals, Inc.

Duration

Period

More charts

Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENZON PHARMACEUTICALS, INC.	-11.86%	6.12M
REGENERON PHARMACEUTICALS, INC.	+10.44%	107B
VERTEX PHARMACEUTICALS INCORPORATED	+0.82%	106B
ARGENX SE	+6.72%	23.47B
BIONTECH SE	-13.89%	21.9B
GENMAB A/S	-6.64%	18.77B
WUXI APPTEC CO., LTD.	-37.26%	17.85B
BEIGENE, LTD.	-10.98%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+8.67%	14.41B
SAREPTA THERAPEUTICS, INC.	+41.08%	12.86B

Bio Therapeutic Drugs